DOCSLIB.ORG

(10) Patent No.: US 9.284.543 B2 Wei Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(10) Patent No.: US 9.284.543 B2 Wei Et Al USOO9284543B2 (12) United States Patent (10) Patent No.: US 9.284.543 B2 Wei et al. (45) Date of Patent: Mar. 15, 2016 (54) NEUTRAL ACTIVE SOLUBLE TRUNCATED 5,643,575 A 7/1997 Martinez et al. ........... 424,194.1 PH2O POLYPEPTDES AND USES THEREOF 5,665,069 A 9/1997 Cumer et al. ..... ... 604,116 5,672,662 A 9, 1997 Harris et al. .. 525/408 5,674,533 A 10/1997 Santus et al. ...... ... 424/493 (75) Inventors: GeWei, San Diego, CA (US); 5,705.364 A 1/1998 Etcheverry et al. .......... 435/70.3 Krishnasamy Panneer Selvam, Poway, 5,721,348 A 2/1998 Primakoff ..... 536,221 CA (US); Louis Bookbinder, San 5,733,566 A 3, 1998 Lewis ........ ... 424/426 Diego, CA (US); Gregory I. Frost, Del 5,766,581 A 6/1998 Bartley et al. 424/85.1 MaCA (US) s s 5,795,569 A 8/1998 Bartley et al. 424/85.1 s 5,808.096 A 9/1998 Zalipsky ........... 548,520 5,854,046 A 12/1998 Au-Young et al. ... 435,201 (73) Assignee: Halozyme, Inc., San Diego, CA (US) 5,900.461 A 5/1999 Harris .................. 525,54.11 5,919,455 A 7/1999 Greeninnwald et al. .... 424,178.1 (*) Notice: Subject to any disclaimer, the term of this 5,932,462 A 8/1999 Harris et al. .................. 435.188 patent is extended or adjusted under 35 E. A 3: CCCling al. ......et al. 5. U.S.C. 154(b) by 449 days. 5.990.237 A 1 1/1999 Bentley et al. ... 525,542 6,057,110 A 5/2000 Au-Young et al. ................ 435/6 (21) Appl. No.: 13/385,527 6,103.525. A 8/2000 Stern et al. ........ ... 435,326 6,113,906 A 9, 2000 Greenwald et al. ........ 424,194.1 (22) Filed: Feb. 21, 2012 6,123,938 A 9, 2000 Stern et al. .... ... 424/94.62 6,193,963 B1 2/2001 Stern et al. 424/94.6 O O 6,214,966 B1 4/2001 Harris ... 528,322 (65) Prior Publication Data 6,258,351 B1 7/2001 Harris ... 424/78.3 US 2012/0213767 A1 Aug. 23, 2012 6,340,742 B1 1/2002 Burg et al. 530,351 6,413.507 B1 7/2002 Bentley et al. ... 42478 US 2013/0101577 A9 Apr. 25, 2013 6.420,339 B1 7/2002 Gegg et al. ... 514/12 6,437,025 B1 8/2002 Harris et al. .. 523,406 Related U.S. Application Data 6,448,369 B1 9/2002 Bentley et al. ... 528/425 6,461,802 B1 10/2002 Van Thillo et al. ... 430,336 (63) Continuation of application No. 127653.245, filed on 6,461,863 B1 10/2002 Jarvis ......................... 435/320.1 Dec. 9, 2009. (Continued) (60) Provisional application No. 61/281,240, filed on Nov. 13, 2009, provisional application No. 61/201,384, FOREIGN PATENT DOCUMENTS filed on Dec. 9, 2008. CA 23.18356 T 2000 EP O400472 12/1990 (51) Int. Cl. CI2N 9/26 (2006.01) (Continued) A6 IK 47/48 (2006.01) A61 K38/00 (2006.01) OTHER PUBLICATIONS (52) U.S. Cl. Letter/Written Disclosure of the Supplemental Information Disclo CPC .......... CI2N 9/2408 (2013.01); A61 K47/4823 sure Statement for the above-referenced application, mailed on Nov. (2013.01); A61 K47/48215 (2013.01); A61 K 13, 2013, 2 pages. 47/48292 (2013.01); C12N 9/2474 (2013.01); Dyson et al., “Production of soluble mammalian proteins in A61 K38/00 (2013.01) Escherichia coli: identification of protein features that correlate with (58) Field of Classification Search successful expression.” BMC Biotechnol. 4:32 (2004). Gayle et al., “Identification of regions in interleukin-1 alpha impor CPC ............................ C12N 9/2408; C12N 9/2474 tant for activity.” J Biol Chem. 268(29): 22105-221 11 (1993). See application file for complete search history. Moran et al., “Glycophospholipid membrane anchor attachment. Molecular analysis of the cleavage attachment site.” J Biol Chem. (56) References Cited 266(2): 1250-1257 (1991). Vigdorovich et al., “Expression and characterization of a soluble, U.S. PATENT DOCUMENTS active form of the jaagsiekte sheep retrovirus receptor, Hyal2. J 3,536,809 A 10/1970 AppleZweig .................... 424,28 Virol. 79(1):79-86 (2005). 3,710,795 A 1/1973 Higuchi et al. ... 424/424 (Continued) 4,002,531 A 1/1977 Royer .......... ... 435,188 4,364,923 A 12/1982 Cook et al. ...................... 424/46 4,952.496 A 8, 1990 Studier et al. 435,9141 Primary Examiner — Sheridan Swope $835 A 88: as: . .3.26 (74) Attorney, Agent, or Firm — Dentons US LLP: 5,059,595 A 10/1991 Le Grazie ... 424/468 Stephanie Seidman 5,073,543 A 12/1991 Marshall et al. 514/21 5,116,615 A 5/1992 Gokcen et al. ...... ... 424/94.2 5, 120,548 A 6, 1992 McClelland et al. ... 424/473 (57) ABSTRACT 5,122,614 A 6/1992 Zalipsky ......... ... 548,520 Soluble PH20 polypeptides are provided, including extended 5,292,509 A 3/1994 Hageman . 424/94.61 5,323,907 A 6/1994 Kalvelage ..................... 206,531 soluble PH20 polypeptides, and uses thereof. Also provided 5,324,844 A 6/1994 Zalipsky ....................... 548,520 are other C-terminally truncated PH20 polypeptides and par 5,446,090 A 8, 1995 Harris ...... 525,54.1 tially deglycosylated PH20 polypeptides and uses thereof. 5,591,767 A 1/1997 Mohr et al. ... 514,413 5,612.460 A 3/1997 Zalipsky ...... 530.391.9 5,639,476 A 6, 1997 Oshlack et al. ............... 424/468 22 Claims, 6 Drawing Sheets US 9,284.543 B2 Page 2 (56) References Cited 2012fO294.830 A1 11/2012 Bookbinder et al. ........ 424/85.2 2013, OO11378 A1 1/2013 Yang et al. ...... ... 424/94.3 U.S. PATENT DOCUMENTS 2013/0022.588 A1 1/2013 Yang et al. ... ... 424/94.3 2013/0022592 A1 1/2013 Vaughn et al. ............. 424/94.62 6,495,659 B2 12, 2002 Bentley et al. ................ 528/425 2013,0058893 A1 3/2013 Bookbinder et al. ......... 435/200 6,552,170 B1 4, 2003 Thompson et al. 530,351 2013/0202583 A1 8/2013 Jiang et al. ...... 424/94.62 6,737,505 B2 5, 2004 Bentley et al. ................ 528/425 2013/0251786 A1 9/2013 Li et al. .... ... 424/94.62 2013/0302275 A1 11, 2013 Wei et al. ..... 424/94.62 6,745,776 B2 6, 2004 Soll ............................... 128/898 6,828.401 B2 12, 2004 Nho et al. ... 526,333 2013/0302400 A1 11/2013 Maneval et al. .............. 435/195 6,828,431 B1 12, 2004 Frudakis et al. 536,231 2014/0037613 A1 2/2014 Bookbinder et al. ...... 424/94.62 6,858,736 B2 2, 2005 Nho et al. .......... 546,290 2014,0199282 A1 7/2014 Bookbinder et al. ......... 435/200 7,015,253 B2 3, 2006 Escandon et al. .. 514,724 2014/0248237 A1 9/2014 Bookbinder et al. ...... 424/94.62 7,105,330 B2 9, 2006 Stern et al. ..... 435/200 7,148,201 B2 12, 2006 Stern et al. .. 514,44 R FOREIGN PATENT DOCUMENTS 7,368, 108 B2 5/2008 DeFrees et al. .... 424/94.5 7,601,335 B2 10, 2009 McCutcheon et al. ......... 424.9.2 EP O822199 9, 2004 7,767.429 B2 8, 2010 Frost et al. .................... 435,201 JP A-2008-531017 8, 2008 7,781,397 B2 8, 2010 Stern et al. ......... 424/94.62 JP 5-670913 2, 2015 7,829,081 B2 11, 2010 Bookbinder et al. 424/94.62 WO WO 88,02261 4f1988 7,846,431 B2 12, 2010 Bookbinder et al. ...... 424/94.62 WO WO 2004/078140 9, 2004 7,871,607 B2 1, 2011 Bookbinder et al. ...... 424/94.62 WO WO 2006/09 1871 8, 2006 7.914,542 B2 3, 2011 Lamson et al. ....... ... 606,139 WO WO 2006,133553 12/2006 8, 105,586 B2 1, 2012 Bookbinder et al. 424/94.3 WO WO 2008.101.098 8, 2008 8, 187,855 B2 5, 2012 Baker et al. ........... ... 435,201 WO WO 2009/128917 10/2009 8,257,699 B2 9, 2012 Bookbinder et al. ...... 424/94.62 WO WO 201O/O77297 T 2010 8,343,487 B2 1, 2013 Baker et al. ................ 424/94.62 8,431,124 B2 4, 2013 Bookbinder et al. ...... 424/94.62 OTHER PUBLICATIONS 8,431,380 B2 4, 2013 Bookbinder et al. ......... 435/201 Whisstock, J. and A. Lesk, “Prediction of protein function from 8.450,470 B2 5, 2013 Bookbinder et al. ........ 536,232 protein sequence and structure.” Q Rev Biophys. 36(3):307-340 8,580,252 B2 11, 2013 Bookbinder et al. 424/85.2 (2003). 8,765,685 B2 T/2014 Bookbinder et al. 514, 20.9 Willard et al., “Expression, purification, and characterization of the 8,772.246 B2 T/2014 Bookbinder et al. ......... 435/200 human receptor activator of NF-kappaB ligand (RANKL) extracel 8,846,034 B2 9, 2014 Jiang et al. ......... 424/94.62 8,927,249 B2 1/2015 Wei et al. ... 424/450 lular domain.” Protein Expr Purif. 2001);48-57 (2000). 2001/OO21763 A1 9, 2001 Harris ...... 528,75 Halozyme Therapeutics Investor Presentation, "Halozyme Thera 2001/0044526 A1 11, 2001 Shen ........... 530/409 peutics, Inc.: Thinking outside the cell.” Presented on Oct. 2, 2012 2001 0046481 A1 11/2001 Bentley et al. 424/78.18 online retrieved on Oct. 11, 2012 Retrieved from:<URL: sec.gov/ 2002fOO52430 A1 5, 2002 Harris et al. .................. 523,406 Archives/edgar/data 1159036/0001 19312512412748/ 20O2/OO72573 A1 6, 2002 Bentley et al.
Load more

Recommended publications
  • Hyaluronidase PH20 (SPAM1) Rabbit Polyclonal Antibody – TA337855
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA337855 Hyaluronidase PH20 (SPAM1) Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: WB Recommended Dilution: WB Reactivity: Human Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: The immunogen for anti-SPAM1 antibody is: synthetic peptide directed towards the C- terminal region of Human SPAM1. Synthetic peptide located within the following region: CYSTLSCKEKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYNASP Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Note that this product is shipped as lyophilized powder to China customers. Purification: Affinity Purified Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 58 kDa Gene Name: sperm adhesion molecule 1 Database Link: NP_694859 Entrez Gene 6677 Human P38567 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 Hyaluronidase PH20 (SPAM1) Rabbit Polyclonal Antibody – TA337855 Background: Hyaluronidase degrades hyaluronic acid, a major structural proteoglycan found in extracellular matrices and basement membranes. Six members of the hyaluronidase family are clustered into two tightly linked groups on chromosome 3p21.3 and 7q31.3. This gene was previously referred to as HYAL1 and HYA1 and has since been assigned the official symbol SPAM1; another family member on chromosome 3p21.3 has been assigned HYAL1.
    [Show full text]
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A
    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
    [Show full text]
  • Mammalian Male Germ Cells Are Fertile Ground for Expression Profiling Of
    REPRODUCTIONREVIEW Mammalian male germ cells are fertile ground for expression profiling of sexual reproduction Gunnar Wrobel and Michael Primig Biozentrum and Swiss Institute of Bioinformatics, Klingelbergstrasse 50-70, 4056 Basel, Switzerland Correspondence should be addressed to Michael Primig; Email: [email protected] Abstract Recent large-scale transcriptional profiling experiments of mammalian spermatogenesis using rodent model systems and different types of microarrays have yielded insight into the expression program of male germ cells. These studies revealed that an astonishingly large number of loci are differentially expressed during spermatogenesis. Among them are several hundred transcripts that appear to be specific for meiotic and post-meiotic germ cells. This group includes many genes that were pre- viously implicated in spermatogenesis and/or fertility and others that are as yet poorly characterized. Profiling experiments thus reveal candidates for regulation of spermatogenesis and fertility as well as targets for innovative contraceptives that act on gene products absent in somatic tissues. In this review, consolidated high density oligonucleotide microarray data from rodent total testis and purified germ cell samples are analyzed and their impact on our understanding of the transcriptional program governing male germ cell differentiation is discussed. Reproduction (2005) 129 1–7 Introduction 2002, Sadate-Ngatchou et al. 2003) and the absence of cAMP responsive-element modulator (Crem) and deleted During mammalian male
    [Show full text]
  • Gene Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section Mini Review SPAM1 (sperm adhesion molecule 1 (PH -20 hyaluronidase, zona pellucida binding)) Asli Sade, Sreeparna Banerjee Department of Biology, Middle East Technical University, Ankara 06531, Turkey (AS, SB) Published in Atlas Database: March 2010 Online updated version : http://AtlasGeneticsOncology.org/Genes/SPAM1ID42361ch7q31.html DOI: 10.4267/2042/44921 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology are clustered on chromosome 3p21.3 and the other Identity three (HYAL4, SPAM1 and HYALP1) are clustered on Other names: EC 3.2.1.35, HYA1, HYAL1, HYAL3, chromosome 7q31.3. Of the three genes on HYAL5, Hyal-PH20, MGC26532, PH-20, PH20, chromosome 7q31.3, HYALP1 is an expressed SPAG15 pseudogene. The extensive homology between the six HGNC (Hugo): SPAM1 hyaluronidase genes suggests an ancient gene duplication event before the emergence of modern Location: 7q31.32 mammals. Local order: According to NCBI Map Viewer, genes flanking SPAM1 in centromere to telomere direction Description on 7q31.3 are: According to Entrez Gene, SPAM1 gene maps to locus - HYALP1 7q31.3 hyaluronoglucosaminidase NC_000007 and spans a region of 46136 bp. According pseudogene 1 to Spidey (mRNA to genomic sequence alignment - HYAL4 7q31.3 hyaluronoglucosaminidase 4 tool), SPAM1 has 7 exons, the sizes being 78, 112, - SPAM1 7q31.3 sperm adhesion molecule 1 1160, 90, 441, 99 and 404. - TMEM229A 7q31.32 transmembrane protein 229A - hCG_1651160 7q31.33 SSU72 RNA polymerase II Transcription CTD phosphatase homolog pseudogene The SPAM1 mRNA has two isoforms; transcript Note: SPAM1 is a glycosyl-phosphatidyl inositol variant 1 (NM_003117) a 2395 bp mRNA and (GPI)-anchored enzyme found in all mammalian transcript variant 2 (NM_153189) a 2009 bp mRNA.
    [Show full text]
  • Hyaluronidase PH20 (SPAM1) (NM 003117) Human Mass Spec Standard – PH305378 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for PH305378 Hyaluronidase PH20 (SPAM1) (NM_003117) Human Mass Spec Standard Product data: Product Type: Mass Spec Standards Description: SPAM1 MS Standard C13 and N15-labeled recombinant protein (NP_003108) Species: Human Expression Host: HEK293 Expression cDNA Clone RC205378 or AA Sequence: Predicted MW: 58.2 kDa Protein Sequence: >RC205378 representing NM_003117 Red=Cloning site Green=Tags(s) MGVLKFKHIFFRSFVKSSGVSQIVFTFLLIPCCLTLNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDM SLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITGVTVNGGIPQKISLQDHLDKAKKDITFYMPVDNL GMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLL RPNHLWGYYLFPDCYNHHYKKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAATLYVRN RVREAIRVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDELVYTFGETVALGASGIVIWGTLSIMRSMKS CLLLDNYMETILNPYIINVTLAAKMCSQVLCQEQGVCIRKNWNSSDYLHLNPDNFAIQLEKGGKFTVRGK PTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYNASPSTLS ATMFIWRLEVWDQGISRIGFF TRTRPLEQKLISEEDLAANDILDYKDDDDKV Tag: C-Myc/DDK Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Concentration: 50 ug/ml as determined by BCA Labeling Method: Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine Buffer: 100 mM glycine, 25 mM Tris-HCl, pH 7.3. Store at -80°C. Avoid repeated freeze-thaw cycles. Stable for 3 months from receipt of products under proper storage and handling conditions. RefSeq:
    [Show full text]
  • HYAL1LUCA-1, a Candidate Tumor Suppressor Gene on Chromosome 3P21.3, Is Inactivated in Head and Neck Squamous Cell Carcinomas by Aberrant Splicing of Pre-Mrna
    Oncogene (2000) 19, 870 ± 878 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA Gregory I Frost1,3, Gayatry Mohapatra2, Tim M Wong1, Antonei Benjamin Cso ka1, Joe W Gray2 and Robert Stern*,1 1Department of Pathology, School of Medicine, University of California, San Francisco, California, CA 94143, USA; 2Cancer Genetics Program, UCSF Cancer Center, University of California, San Francisco, California, CA 94115, USA The hyaluronidase ®rst isolated from human plasma, genes in the process of carcinogenesis (Sager, 1997; Hyal-1, is expressed in many somatic tissues. The Hyal- Baylin et al., 1998). Nevertheless, functionally 1 gene, HYAL1, also known as LUCA-1, maps to inactivating point mutations are generally viewed as chromosome 3p21.3 within a candidate tumor suppressor the critical `smoking gun' when de®ning a novel gene locus de®ned by homozygous deletions and by TSG. functional tumor suppressor activity. Hemizygosity in We recently mapped the HYAL1 gene to human this region occurs in many malignancies, including chromosome 3p21.3 (Cso ka et al., 1998), con®rming its squamous cell carcinomas of the head and neck. We identity with LUCA-1, a candidate tumor suppressor have investigated whether cell lines derived from such gene frequently deleted in small cell lung carcinomas malignancies expressed Hyal-1 activity, using normal (SCLC) (Wei et al., 1996). The HYAL1 gene resides human keratinocytes as controls. Hyal-1 enzyme activity within a commonly deleted region of 3p21.3 where a and protein were absent or markedly reduced in six of potentially informative 30 kb homozygous deletion has seven carcinoma cell lines examined.
    [Show full text]
  • Hyaluronidase PH20 (SPAM1) (NM 001174045) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RG230203 Hyaluronidase PH20 (SPAM1) (NM_001174045) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: Hyaluronidase PH20 (SPAM1) (NM_001174045) Human Tagged ORF Clone Tag: TurboGFP Symbol: SPAM1 Synonyms: HEL-S-96n; HYA1; HYAL1; HYAL3; HYAL5; PH-20; PH20; SPAG15 Vector: pCMV6-AC-GFP (PS100010) E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 5 Hyaluronidase PH20 (SPAM1) (NM_001174045) Human Tagged ORF Clone – RG230203 ORF Nucleotide >RG230203 representing NM_001174045 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGGAGTGCTAAAATTCAAGCACATCTTTTTCAGAAGCTTTGTTAAATCAAGTGGAGTATCCCAGATAG TTTTCACCTTCCTTCTGATTCCATGTTGCTTGACTCTGAATTTCAGAGCACCTCCTGTTATTCCAAATGT GCCTTTCCTCTGGGCCTGGAATGCCCCAAGTGAATTTTGTCTTGGAAAATTTGATGAGCCACTAGATATG AGCCTCTTCTCTTTCATAGGAAGCCCCCGAATAAACGCCACCGGGCAAGGTGTTACAATATTTTATGTTG ATAGACTTGGCTACTATCCTTACATAGATTCAATCACAGGAGTAACTGTGAATGGAGGAATCCCCCAGAA GATTTCCTTACAAGACCATCTGGACAAAGCTAAGAAAGACATTACATTTTATATGCCAGTAGACAATTTG GGAATGGCTGTTATTGACTGGGAAGAATGGAGACCCACTTGGGCAAGAAACTGGAAACCTAAAGATGTTT
    [Show full text]
  • Characterization of Recombinant Bovine Sperm Hyaluronidase And
    J. Microbiol. Biotechnol. (2018), 28(9), 1547–1553 https://doi.org/10.4014/jmb.1804.04016 Research Article Review jmb Characterization of Recombinant Bovine Sperm Hyaluronidase and Identification of an Important Asn-X-Ser/Thr Motif for Its Activity Chaeri Park1†, Young-Hyun Kim2,3†, Sang-Rae Lee2,3†, Soojin Park4, Yena Jung1, Youngjeon Lee2,3, Ji-Su Kim2,3, Taekil Eom5, Ju-Sung Kim5, Dong-Mok Lee6, Bong-Suk Song2,3, Bo-Woong Sim2, Sun-Uk Kim2,3, Kyu-Tae Chang2,3*, and Ekyune Kim1* 1College of Pharmacy, Catholic University of Daegu, Gyeongsan 38430, Republic of Korea 2National Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea 3Department of Functional Genomics, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Daejeon 34113, Republic of Korea 4Graduate School of Medicine, Osaka University, Suita, Osaka 5650871, Japan 5College of Applied Life Sciences, the Research Institute for Subtropical Agriculture and Biotechnology, Jeju National University, Jeju 63249, Republic of Korea 6Daegyeong Regional Division, Technology Convergence R&BD Group, Korea Institute of Industrial Technology, Yeongcheon 38822, Republic of Korea Received: April 16, 2018 Revised: July 3, 2018 Hyaluronidases are a family of enzymes that catalyse the breakdown of hyaluronic acid, Accepted: July 19, 2018 which is abundant in the extracellular matrix and cumulus oocyte complex. To investigate the First published online activity of recombinant bovine sperm hyaluronidase 1 (SPAM1) and determine the effect of July 19, 2018 the Asn-X-Ser/Thr motif on its activity, the bovine SPAM1 open reading frame was cloned *Corresponding author into the mammalian expression vector pCXN2 and then transfected to the HEK293 cell line.
    [Show full text]
  • Insights Into the Mechanism of Bovine Spermiogenesis Based on Comparative Transcriptomic Studies
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.25.313908; this version posted September 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Insights into the mechanism of bovine spermiogenesis based on comparative transcriptomic studies Xin Li 1, Chenying Duan 2, Ruyi Li 2, Dong Wang 1,* 1 Institute of Animal Science, Chinese Academy of Agricultural Sciences, 100193 Beijing, China 2 College of Animal Science and Technology, Jilin Agricultural University, 130118 Changchun, China * Corresponding author: Dong Wang E-mail: [email protected] Keywords: Spermiogenesis, Differentially expressed genes, Homology trends analysis, Protein-regulating network, ADP-ribosyltransferase 3 (ART3) 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.25.313908; this version posted September 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. (2), resulting in a tremendous waste. At the same Abstract time, about 15% of the couples of childbearing age worldwide are affected by infertility, of To reduce the reproductive loss caused by which 50% are due to male factors (3), and even semen quality and provide theoretical guidance sperm with normal morphology can cause
    [Show full text]
  • Dissecting the Genetics of Human Communication
    DISSECTING THE GENETICS OF HUMAN COMMUNICATION: INSIGHTS INTO SPEECH, LANGUAGE, AND READING by HEATHER ASHLEY VOSS-HOYNES Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Epidemiology and Biostatistics CASE WESTERN RESERVE UNIVERSITY January 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We herby approve the dissertation of Heather Ashely Voss-Hoynes Candidate for the degree of Doctor of Philosophy*. Committee Chair Sudha K. Iyengar Committee Member William Bush Committee Member Barbara Lewis Committee Member Catherine Stein Date of Defense July 13, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein Table of Contents List of Tables 3 List of Figures 5 Acknowledgements 7 List of Abbreviations 9 Abstract 10 CHAPTER 1: Introduction and Specific Aims 12 CHAPTER 2: Review of speech sound disorders: epidemiology, quantitative components, and genetics 15 1. Basic Epidemiology 15 2. Endophenotypes of Speech Sound Disorders 17 3. Evidence for Genetic Basis Of Speech Sound Disorders 22 4. Genetic Studies of Speech Sound Disorders 23 5. Limitations of Previous Studies 32 CHAPTER 3: Methods 33 1. Phenotype Data 33 2. Tests For Quantitative Traits 36 4. Analytical Methods 42 CHAPTER 4: Aim I- Genome Wide Association Study 49 1. Introduction 49 2. Methods 49 3. Sample 50 5. Statistical Procedures 53 6. Results 53 8. Discussion 71 CHAPTER 5: Accounting for comorbid conditions 84 1. Introduction 84 2. Methods 86 3. Results 87 4. Discussion 105 CHAPTER 6: Hypothesis driven pathway analysis 111 1. Introduction 111 2. Methods 112 3. Results 116 4.
    [Show full text]
  • Detection of Copy Number Alterations in Metastatic Melanoma by a DNA
    Human Cancer Biology Detection of Copy Number Alterations in Metastatic Melanoma by aDNAFluorescenceIn situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431) Stephen R. Moore,1Diane L. Persons,2 Jeffrey A. Sosman,3 Dolores Bobadilla,1Victoria Bedell,1 David D. Smith,1Sandra R.Wolman,4 Ralph J. Tuthill,5 Jim Moon,6 Vernon K. Sondak,7 and Marilyn L. Slovak1 Abstract Purpose: Gene copy number alteration (CNA) is common in malignant melanoma and is associated with tumor development and progression. The concordance between molecular cytogenetic techniques used to determine CNA has not been evaluated on a large set of loci in malignant melanoma. Experimental Design: A panel of 16 locus-specific fluorescence in situ hybridization (FISH) probes located on eight chromosomes was used to identify CNA in touch preparations of frozen tissue samples from19 patients with metastaticmelanoma (SWOG-9431). A subset ( n =11)was analyzed using bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH) of DNA isolated directly from touch-preparation slides. Results: By FISH, most samples showed loss near or at WISP3 /6p21, CCND3/6q22, and CDKN2A /9p21 (>75% of samples tested). More than one third of CDKN2A /9p21losses were biallelic. Gains of NEDD9/6p24, MET/7q31, and MYC/8q24 were common (57%, 47%, and 41%, respectively) and CNA events involving 9p21/7p12.3 and MET were frequently coincident, suggesting gain of the whole chromosome 7. Changes were confirmed by aCGH, which also uncovered many discreet regions of change, larger than a single BAC. Overlapping segments observed in >45% of samples included many of the loci analyzed in the FISH study, in addition to other WNT pathway members, and genes associated withTP53 pathways and DNA damage response, repair, and stability.
    [Show full text]
  • Atlas Journal
    Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 12, Number 4, Jul-Aug 2008 Previous Issue / Next Issue Genes AKR1C3 (aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)) (10p15.1). Hsueh Kung Lin. Atlas Genet Cytogenet Oncol Haematol 2008; Vol (12): 498-502. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/AKR1C3ID612ch10p15.html CASP1 (caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)) (11q22.3). Yatender Kumar, Vegesna Radha, Ghanshyam Swarup. Atlas Genet Cytogenet Oncol Haematol 2008; Vol (12): 503-518. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CASP1ID145ch11q22.html GCNT3 (glucosaminyl (N-acetyl) transferase 3, mucin type) (15q21.3). Prakash Radhakrishnan, Pi-Wan Cheng. Atlas Genet Cytogenet Oncol Haematol 2008; Vol (12): 519-524. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/GCNT3ID44105ch15q21.html HYAL2 (Hyaluronoglucosaminidase 2) (3p21.3). Lillian SN Chow, Kwok-Wai Lo. Atlas Genet Cytogenet Oncol Haematol 2008; Vol (12): 525-529. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/HYAL2ID40904ch3p21.html LMO2 (LIM domain only 2 (rhombotin-like 1)) (11p13) - updated. Pieter Van Vlierberghe, Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2008; Vol (12): 530-535. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/RBTN2ID34.html PEBP1 (phosphatidylethanolamine binding protein 1) (12q24.23).
    [Show full text]